Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(-3.03%)
HKD 0.03
(-3.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 76.63 Million HKD | -170.5% |
| 2022 | 26.92 Million HKD | -18.42% |
| 2021 | 112.17 Million HKD | -44.9% |
| 2020 | 156.3 Million HKD | -60.07% |
| 2019 | 419.17 Million HKD | 65.44% |
| 2018 | 259.81 Million HKD | 141.41% |
| 2017 | 134.87 Million HKD | 460.78% |
| 2016 | 30.71 Million HKD | 75.77% |
| 2015 | 14.9 Million HKD | -85.17% |
| 2014 | 82.89 Million HKD | 5.91% |
| 2013 | 89.66 Million HKD | -20.93% |
| 2012 | 71.38 Million HKD | -32.84% |
| 2011 | 142.15 Million HKD | -73.34% |
| 2010 | 534.45 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 58.35 Million HKD | 0.0% |
| 2023 Q1 | -6.92 Million HKD | 22.73% |
| 2023 Q2 | -17.42 Million HKD | -151.63% |
| 2023 FY | - HKD | -170.5% |
| 2023 Q4 | -41.57 Million HKD | -131.06% |
| 2023 Q3 | -17.99 Million HKD | -3.27% |
| 2022 Q1 | -7.18 Million HKD | -112.58% |
| 2022 FY | - HKD | -18.42% |
| 2022 Q4 | -8.96 Million HKD | 73.93% |
| 2022 Q3 | -34.36 Million HKD | -394.87% |
| 2022 Q2 | -6.94 Million HKD | 3.28% |
| 2021 FY | - HKD | -44.9% |
| 2021 Q1 | -15.65 Million HKD | 49.03% |
| 2021 Q2 | 9.82 Million HKD | 162.74% |
| 2021 Q3 | 13.03 Million HKD | 32.66% |
| 2021 Q4 | 57.09 Million HKD | 338.18% |
| 2020 FY | - HKD | -60.07% |
| 2020 Q1 | 20.15 Million HKD | 140.77% |
| 2020 Q2 | 170.21 Million HKD | 744.5% |
| 2020 Q4 | -30.71 Million HKD | 0.0% |
| 2019 Q2 | 188.71 Million HKD | 160.94% |
| 2019 Q3 | 79.2 Million HKD | -58.03% |
| 2019 Q1 | 72.32 Million HKD | 59.28% |
| 2019 FY | - HKD | 65.44% |
| 2019 Q4 | -49.44 Million HKD | -162.42% |
| 2018 Q2 | 61.2 Million HKD | 0.0% |
| 2018 Q4 | 45.4 Million HKD | 0.0% |
| 2018 FY | - HKD | 141.41% |
| 2018 Q1 | 61.2 Million HKD | 159.63% |
| 2018 Q3 | 45.4 Million HKD | -25.82% |
| 2017 Q1 | 23 Million HKD | 668.58% |
| 2017 FY | - HKD | 460.78% |
| 2017 Q4 | 23.57 Million HKD | 0.0% |
| 2017 Q3 | 23.57 Million HKD | 2.47% |
| 2017 Q2 | 23 Million HKD | 0.0% |
| 2016 Q2 | -7 Million HKD | 0.0% |
| 2016 Q4 | 2.99 Million HKD | 0.0% |
| 2016 Q3 | 2.99 Million HKD | 142.74% |
| 2016 Q1 | -7 Million HKD | 11.39% |
| 2016 FY | - HKD | 75.77% |
| 2015 Q2 | -811.5 Thousand HKD | 0.0% |
| 2015 Q3 | -7.9 Million HKD | -874.06% |
| 2015 Q4 | -7.9 Million HKD | 0.0% |
| 2015 FY | - HKD | -85.17% |
| 2015 Q1 | -811.5 Thousand HKD | -125.04% |
| 2014 Q3 | 3.24 Million HKD | -78.74% |
| 2014 Q4 | 3.24 Million HKD | 0.0% |
| 2014 Q2 | 15.24 Million HKD | 0.0% |
| 2014 Q1 | 15.24 Million HKD | -5.92% |
| 2014 FY | - HKD | 5.91% |
| 2013 Q3 | 16.2 Million HKD | 139.04% |
| 2013 FY | - HKD | -20.93% |
| 2013 Q1 | 6.77 Million HKD | 240.63% |
| 2013 Q2 | 6.77 Million HKD | 0.0% |
| 2013 Q4 | 16.2 Million HKD | 0.0% |
| 2012 FY | - HKD | -32.84% |
| 2012 Q3 | -4.82 Million HKD | -131.57% |
| 2012 Q2 | 15.27 Million HKD | 0.0% |
| 2012 Q4 | -4.82 Million HKD | 0.0% |
| 2012 Q1 | 15.27 Million HKD | 0.0% |
| 2011 Q2 | 32.4 Million HKD | 0.0% |
| 2011 Q4 | 15.27 Million HKD | -52.88% |
| 2011 FY | - HKD | -73.34% |
| 2011 Q1 | 32.4 Million HKD | 0.0% |
| 2011 Q3 | 32.4 Million HKD | 0.0% |
| 2010 Q4 | 32.4 Million HKD | -60.28% |
| 2010 Q1 | 81.59 Million HKD | 0.0% |
| 2010 Q2 | 81.59 Million HKD | 0.0% |
| 2010 FY | - HKD | 0.0% |
| 2010 Q3 | 81.59 Million HKD | 0.0% |
| 2009 Q4 | 81.59 Million HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 49.047% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 97.417% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 159.167% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 32.659% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 252.567% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 30.219% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 81.683% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 392.839% |
| SSY Group Limited | 2.11 Billion HKD | 96.376% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 62.506% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 82.175% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.503% |